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Radiation dermatitis is a common side effect of external beam radiation therapy. The 
purpose of this study was to evaluate the effectiveness of applying an aloe vera based skin 
gel to the target area skin in preventing the development of radiation dermatitis to post-
lumpectomy/mastectomy patients receiving external beam radiation therapy in an ambulatory 
radiation-oncology clinic in the southeastern region of the United States. In this descriptive 
correlational study, a convenience sample of willing participants (n=18) was followed from 
initial treatment through the one-month follow-up examination to assess the intensity of their 
skin reaction. 
Five research questions were examined pertaining to the relationship 
between prognostic indicators and the development of radiation dermatitis when Radiacare® 
gel was used before and throughout external beam radiation therapy post-mastectomy or 
post-lumpectomy. The prognostic indicators used in this study were: Breast size > C-cup, 
prior chemotherapeutic exposure, length of incision, age of client, and weight changes since 
diagnosis. Analysis of Variance (ANOVA) and Pearson's Correlation Coefficients were 
used in the data analysis with a confidence of p=0.05. This study indicated that breast size 
and weight changes were the most prognostic of the factors studied. 
The small sample size and lack of randomization or control group limit the generalizability of 
these findings to clinical practice; however, it does support the need for continued research in 
this area. Recommendations for future studies include comparing Body Mass Index (BMI) to 
incidence and determining a relationship between gel use and treatment breaks and if there is 
a difference in the length of time until the skin is restored to baseline upon completion of 
therapy. 
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PREVENTION OF RADIATION-INDUCED SKIN REACTIONS 
IN BREAST CANCER EXTERNAL IRRADIATION 
Chapter I 
Significance 
Radiation dermatitis is a common and sometimes debilitating side effect experienced 
by post-lumpectomy/mastectomy clients receiving external beam radiation therapy. 
Many factors have been identified as contributing to the development of radiation 
dermatitis including breast tissue greater than C-cup, size of lumpectomy/mastectomy 
scar, use of radiosensitive medications (including chemotherapeutic agents), age and poor 
nutritional status. Knowledge of these factors can be used by healthcare professionals to 
predict which patients could benefit from aggressive prevention of this complication. 
Nurses assist women to deal with the devastating emotional, spiritual and physical 
effects that encompass the diagnosis and treatment of breast cancer. Since there are 
many changes with which the client will have to cope, the prevention of problems 
associated with the treatment of this disease becomes of primary importance to both the 
client and nurse. Many women are choosing breast conserving surgery and adjunctive 
irradiation of the remaining breast tissue as their treatment option when faced with the 
diagnosis of breast cancer (Kolcaba and Fox, 1999). Other women are choosing to 
receive chest wall irradiation following mastectomy. It is known that as many as 95 
percent of patients receiving external beam radiation therapy will experience radiation 
induced skin changes known as radiation dermatitis (Porock, Nikoletti & Kristjanson, 
1999). Some skin reactions are mildly irritating, while others may require interruption of 
treatment schedule (Williams et. al., 1996). Some reactions are so severe that ulceration, 
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infection and/or necrosis of tissue will occur (Archambeau, Penzer & Wasserman, 1995). 
Since cosmesis is often a factor when selecting lumpectomy and radiation, prevention of 
severe side effects are important because these complications could lead to permanent 
scarring and loss of affected tissue (Archambeau et. al., 1995). Archambeau and 
colleagues (1995) also noted that the development of the most severe chronic skin 
reactions were seen in those clients who developed the more severe acute skin reactions. 
Hoskins (1997) also noted that women who did not develop side effects from treatment 
reported less psychological distress and a greater perceived health status than those who 
did. It is also known that the psychological attitude of the clients and their perceived 
health status can greatly affect the outcome of the treatment. Since nursing is charged 
with assisting the clients to deal with and prevent problems associated with their 
treatment process, and external beam irradiation is known to cause irritating or 
debilitating skin reactions, identification of an agent that could prevent those skin 
reactions without adverse reactions is desirable. 
Purpose Statement 
The purpose of this study was to evaluate the effectiveness of applying an aloe vera 
based skin gel to the target area skin in preventing the development of radiation 
dermatitis to post-I umpectomy/mastectomy clients receiving external beam radiation 
therapy in an ambulatory radiation/oncology clinic located in the southeastern region of 
the United States. 
Research Questions 
1. What is the relationship between breast size and the incidence of radiation 
dermatitis when using Radiacare® gel before and throughout external beam 
radiation therapy? 
2. What is the relationship between the prior use of radiosensitive agents and the 
incidence of radiation dermatitis when using Radiacare® gel before and 
throughout external beam radiation therapy? 
3. What is the relationship between the length of the surgical incision and the 
incidence of radiation dermatitis when using Radiacare® gel before and 
throughout external beam radiation therapy? 
4. What is the relationship between the age of the client and the incidence of 
radiation dermatitis when using Radiacare® gel before and throughout external 
beam radiation therapy? 
5. What is the relationship between weight changes since diagnosis and the 
incidence of radiation dermatitis when using Radiacare® gel before and 
throughout external beam radiation therapy? 
Definitions 
Breast Size 
Breast is a term used to describe paired mammary glands located on the anterior 
surface of the thoracic cage. Varying amounts of subcutaneous and retromammary 
adipose tissue provide a vast range in the individual's breast size and shape. Breast size 
is identified as a numerical and letter value placed upon the measurement of the tissue 
and comparing the differences in measurement. 
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The numerical value is recorded in inches and is obtained by measuring the 
circumference of the chest wall immediately inferior to the axillary fold and rounded to 
the nearest even whole number. The letter value is obtained by measuring around the 
fullest point of the bust line and recording this measurement in inches. The difference 
between the two numbers is calculated and a letter value is recorded based upon a the 
following scale: 
Large breast size was classified as a measurement greater than C-cup size in the affected 
breast post operatively. 
Radiosensitive Agents 
Radiosensitivity is the term used to identify any pharmacological or chemotherapeutic 
agent that intensifies the effect of radiation especially upon the skin. A list of all current 
prescription and nonprescription medications including herbal supplements and vitamins 
was obtained from each participant. Those medications were reviewed for known 
radiosensitivity. A history was taken to record current or previous exposure to 
radiosensitizing chemotherapeutic agents; the dosage and the time lapse since last 
chemotherapeutic treatment was recorded. 
Surgical Scar 
Scar tissue develops when there is an interruption of skin integrity. Repair of this 
breech in normal skin tissue is accomplished by the formation of densely packed granular 
tissue commonly referred to as a scar. The length and location of each participant's 
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the quadrants of upper lateral (including tail of Spence), upper medial, lower lateral and 
lower medial as well as mixed lateral, medial, superior, inferior or mastectomy 
(Appendix 1). Clients with edema, erythema, or an open, draining wound in the 
treatment area at the onset of therapy were excluded from the study. 
Age 
Age is a term that reflects the cumulative existence of a person since birth. For this 
study, each participant's age was recorded in years by subtracting the numerical 
representation of the year in which the study was conducted from the numerical 
representation of the year in which the participant was born. 
Weight changes 
The measured relationship between a mass of a body and the effect of gravity is 
conceptualized by the term weight. In this study, the participant was questioned as to 
their weight immediately before the diagnosis of cancer. Weights were measured on the 
day of the initial consultation, weekly throughout the treatment regimen, and again at the 
four-week follow-up appointment. Weights were recorded in pounds and rounded to the 
nearest one-tenth. 
Radiacare® Gel 
Aloe is identified as any number of plants within the lily family from which the sap of 
the spiky leaves can be applied topically to skin insults, including burns, for its 
therapeutic properties. Acemannan hydrogel, an extract of Aloe vera L., is the active 
ingredient in Radiacare® Gel, which is developed and marketed by Carrington 
Laboratories, Inc. It has been approved for prescription use by the Food and Drug 
Administration for the management of skin conditions associated with first and second 
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degree burns, stasis and decubutis ulcers, and superficial skin conditions including 
radiation dermatitis (Plemons, et. al., 1994). Acemannan has been shown to affect direct 
interaction of monocytes and macrophages that is believed to directly affect actions in 
such a manner that epithelialization and collagen deposits are hastened thus improving 
wound healing (McDade, Lutz and Fosmire, 1995). 
Application 
Application is defined as the spreading of a thin layer of a substance to the hand and 
transferring that substance topically to another area to disperse the substance evenly in 
order to receive the desired benefit from that substance. 
Radiacare ® Gel 1.5 ounce sample tubes were given to the clients during the initial 
consultation and simulation visit with a prescription for a four ounce tube with five 
refills. The clients were instructed to apply the gel to the skin within the treatment 
markings two to three times daily from the date of initial consultation continuously 
through the four-week post-radiation follow-up appointment (Appendix 1). 
External Beam Radiation Therapy 
Standard External Beam Radiation (EBR) Therapy is exposure of a defined area to a 
concentration of X-rays with the desired purpose of interrupting the growth of neoplastic 
cells within that area. External Beam Radiation Therapy for post-lumpectomy or 
mastectomy is delivered each weekday in 200 cGy fractions over a period of twenty-five 
(25) consecutive treatments for a total radiation dose of 5000 cGy. An additional Boost 
of 1200 cGy is directed at the site of the lump for a total dose of6200 cGy. 
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Radiation Dermatitis 
Radiation dermatitis is a global term for any adverse skin changes that can be directly 
attributed to external beam radiation therapy. These changes range from erythemia or 
bronzing of the skin within the treatment area to ulceration, infection and necrosis. This 
reaction may be so severe as to interrupt therapy. Many measurement scales have been 
suggested and tested for the accurate assessment of these skin reactions. For this study, a 
six-point descriptive scale was be utilized. This scale, adopted by the Oncology Nursing 
Society (Bruner, et.al, 1998), attempts to standardize the subjective description of 
radiation induced skin reactions. 
Scale: 
Grade I faint or dull erythema, follicular reaction 
Grade II bright erythema 
Grade III dry desquamation with or without erythema 
Grade IV small to moderate amount of wet desquamation 
Grade V confluent moist desquamation; edema 
Grade VI Ulceration, hemorrhage, or necrosis 
Development of a Grade V reaction subjects the client to an interruption in therapy. 
Since radiotherapeutic effects are cumulative, the goal is to avoid disruptions in the 
treatment plan (Archambeau, Pezner & Wasserman, 1995). There are no published 
reliability or validity statistics available on this scale. 
Incidence 
The incidence of radiation dermatitis was calculated by the summation of the total 
skin reaction scores in each site (incision area, inframammary fold, axilla (where 
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appropriate) and overall treatment field) throughout the treatment plan. 
Conceptual map 
The numbers of known and suspect factors contributing to the development of 
radiation dermatitis are beyond the scope of this study and were limited to five. For the 
questions concerning the relationship these five factors have on the incidence of radiation 
dermatitis when using Radiacare® gel before and throughout external beam radiation 
therapy, a conceptual map was drawn as follows: 
It is known that EBR + these listed factors = Radiation Dermatitis. 
+ Large Breast Size 
External + Radiosensitive Agents Radiation 
Beam + Surgical Scar Size + Radiacare ® Gel ? Dermatitis 
Radiation + Age 
+ Weight Changes 
Contributing Factors not addressed in this study 
Fair skin complexions 
Immunocompromisation 
Prolonged Radiation Exposure 
Smoking or History of Skin Cancer 
Non-adherence to recommended skin care 
Postmenopausal state 
Co-morbidity of HPT, CVHD, or 
Autoimmune diseases 
Summary 
No topical agent has been shown to prevent radiation-induced skin reactions in those 
receiving external beam radiation therapy. Since research indicates that 95 % of these 
clients will develop some type of skin reaction, it is imperative that a method of 
preventing this complication be found. Prior studies have focused upon the treatment of 
such skin reactions; however, few have examined methods of prevention. Both nurses 
and clients are interested in preventing potentially debilitating complications and 
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therefore improving the outcomes of the treatment plan. A review of the relevant 
literature was conducted to identify both contributing factors to the incidence of radiation 
dermatitis and agents recommended for prophylactic use. 
Chapter II 
Review of Literature 
In professional literature, the effects of radiation on the skin and breast tissue are 
described. Several studies (Appendix A-2) have been published addressing prognostic 
indicators for severe skin reactions to irradiation. Much has been written about the use of 
topical agents to treat moderate radiation-induced skin reactions while others address the 
most effective treatment plans and dressings for the more severe manifestations; 
however, very few studies have been published that specifically address the prophylaxis 
of radiation-induced dermatitis despite the acknowledgement of possible severe long-
term effects with the development of acute skin reactions. 
Effects of Radiation on the Skin and Breast Tissue 
Radiation has been known to cause skin changes since 1901 when Henri Becquerel 
first developed ulceration while transporting radium in his pocket (Sitton, 1992a). 
Clients may be familiar with the skin changes seen with ultraviolet blue radiation (UVB) 
commonly called "sunburn"; however, the radiation used with external beam radiation 
therapy is quite different from other types of ionizing radiation (Noble-Adams, 1999). 
The rapid abi lity of the normal skin cells to repair themselves from ionizing radiation and 
the inability of the malignant cells to do so is the advantage of radiation therapy (Noble-
Adams, 1999; Archembeau, Penzer & Wasserman, 1995). The reaction of the skin 
ranges from mild erythema to ulceration and necrosis of tissue. 
Prognostic Indicators for Severe Skin Reactions 
Clinicians assumed that the same skin type risks to UVB radiation would also predict 
those most at risk for developing radiation-induced dermatitis; however, studies have 
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failed to support this assumption (Lokkevik et. al, 1996; Williams et al, 1996; Maiche, 
Isokangas & Grohn, 1994; Sitton, 1992). Review of professional literature finds that the 
type of radiation employed, the length of exposure time, the strength of dose and the size 
and location of the treatment field are the most accurate prognostic indicator for 
development of severe skin changes. It was indicated that the longer the exposure time, 
the stronger the dose, or the larger the treatment field, the greater the risk of severe skin 
reaction (Porock, Nickoletti & Kristjanson, 1999; Noble-Adams, 1999; Archembeau et. 
al., 1995; Sitton, 1992). 
An additional factor known to increase risk of severe skin reaction for women 
receiving post-lumpectomy or post-mastectomy irradiation was the concurrent use of 
radiosensitive chemotherapeutic agents (Noble-Adams, 1999; Porok et. al, 1998; 
Turesson et. al., 1996). Other significant prognostic factors for the development of 
severe skin reaction to radiation therapy were identified by Porock and colleagues (1998) 
as smoking, irradiation of appositional skin folds (axillary and inframammaiy), weight or 
large breast size, previous lymph aspiration or resection, wearing tightly fitting clothing, 
and skin-to-skin friction in the treatment field. Other studies have identified age 
(Turesson, et. al, 19%), poor nutritional status (Sitton, 1992) nonadherence to 
recommended skin care (Noble-Adams, 1999; Porock, Nicoletti & Kristjanson; 1999; 
Sitton, 1992), menopausal state (Porock etal, 1998; Turesson et. al., 1996; Sitton, 1992) 
and that which is identified in the literature as "patient-to-patient variability" (Noble-
Adams, 1999; Porock et.al., 1998; Turesson et. al., 1996; Sitton, 1992). It is this 
unknown factor, patient-to-patient variability, that requires prophylactic treatment be 
given to all clients receiving irradiation to the breast or chest wall. Co-morbid existence 
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of disease such as hypertension, cardiovascular disorders, history of skin cancer, and the 
presence of autoimmune diseases are also included as contributory factors (Turesson et. 
al., 1996). 
Use of Topical Agents to Treat Radiation-Induced Skin Reactions 
Much has been written about therapeutic agents used in the treatment of radiation-
induced skin reactions, although there is little empirical evidence to support their 
effectiveness. Mild erythema and dry desquamation have been treated with topical 
ointments including wax, paraffin, olive oil, and almond & chamomile creams with 
discouraging results (Maiche, Grohn, Maki-Hokkovien, 1991). Weak, topical 
corticosteroids such as 1% hydrocortisone and 0.05% clobetasone cream have been used 
but are known to mask signs of infection in inflamed skin (Sitton, 1992). Gleese, 
Mameghan-Zaheh and Sparkes (1979) saw such a severe skin reaction with the use of the 
0.05% clobetasone cream that they recommended discontinuance of the use of topical 
steroids until the causative factor could be identified. Kolcaba & Fox (1999) and Hogan 
(1997) have also published the results of works with guided imagery to manage the 
symptoms of pain, burning, and itching that are associated with the skin reactions. When 
moist desquamation develops, tradition dictated cleansing the area with half-strength 
peroxide and saline then applying 1% gentian violet solution (Porok, Nicoletti & 
Kristanjanson, 1999); however, current evidence discourages the use of peroxide on an 
open, draining wound. Both the use of hydrocolloid (Margolin et al, 1990) and moisture 
vapor permeable dressings (Porock, Nickoletti & Kristjanson, 1999) have been used on 
open draining wounds to heal and prevent infection with promising results. 
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Hydrocortisone versus Clobetasone cream 
Gleese, Mameghan-Zaheh and Sparkes (1979) studied the use of 1% hydrocortisone 
cream or 0.05% clobetasone cream in a double blind randomized study of 54 clients 
receiving external beam radiation therapy for breast cancer. Once the client's radiation 
dosage had reached 2000 rad, they were given one of the creams and instructed to apply a 
thin layer two or three times a day even if no skin reaction was seen. The reaction of the 
clobetasone group's skin was so much worse than the group receiving hydrocortisone that 
the researchers did not recommend the use of either cream until the reason for such a 
reaction could be identified. Modern improvements in the delivery of radiotherapy of the 
radiation beam and narrowing of the irradiation field may encourage a replication study 
of these medications. Application of the creams at the initial treatment visit may also 
improve the outcome as research has identified the early part of the second week of 
treatment as the most frequently seen in the development of erythema (Noble-Adams, 
1999; Archambeau, Pezner & Wasserman, 1995; Sitton, 1992). 
Sucralfate Cream 
The use of sucralfate cream was studied on fifty breast cancer clients receiving 
external beam radiation post-mastectomy or lumpectomy. (Maiche, Isokangas & Groh, 
1994). A double-blind study was utilized with each client acting as her own control. A 
thin layer of either sucralfate cream or a placebo cream was applied to either side of the 
scar beginning with the initial radiation treatment (up to third treatment). The skin was 
evaluated weekly on a five-point scale for degree of skin reaction by either the physician 
or oncology clinic nurse. Sucralfate was selected based on its success with mucosal 
membranes and the hope that the sucralfate would enhance growth of epithelial cells 
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(Maiche et. al., 1994). Their study found that grade I (erythematic) and grade II (dark 
erythema/pain) developed much later on the sucralfate treated side, that healing occurred 
much faster and there was a less likely chance of the development of later skin reactions. 
The findings of this study were encouraging. A larger sample group and replication of 
the use of this medication in other settings would be helpful in validating the findings. 
Dexpanthenol cream 
Lokkevik and colleagues (1996) studied the effects of dexpanthenol cream for its 
prophylactic properties with clients undergoing either breast or laryngeal irradiation. The 
active ingredient in dexpanthenol, panothothenic acid, is known to decrease the effects of 
dermatitis and was selected to promote epithelial formation and regeneration thus 
preventing severe radiation-induced skin reactions. Sixty-three breast cancer clients were 
included in the eighty-six total subjects studied. Twenty-one of those sixty-three were 
receiving concurrent low-dose chemotherapy. This study also used a subjective five-
point scoring system (0 = no reaction, 1 = mild reaction, 2 = moderate reaction, 3 = 
severe reaction, 4 = moist desquamation). Clients were ineligible to participate if they 
had a history of prior skin disease, allergy to the studied agent, were unable to cooperate 
with the study or had their radiation therapy postponed for any reason. This study found 
no clinically significant difference in skin reactions with the use of this cream, and it was 
removed from their clinic's routine skin care protocol. 
Biafine ® burn cream 
Szumacher (2000) reported on a study describing the results of phase two of a clinical 
trial in sixty patients from the Toronto area who were given the burn cream marketed as 
Biafine ® upon initiation of their external beam radiation treatments post mastectomy or 
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lumpectomy. The study used the Oncology Nursing Society scale for recording skin 
reactions. Although eighty-three percent of the clients still developed grade II radiation 
dermatitis, only six percent developed grade III and no one developed the most severe 
forms, grade IV and V. She indicated that while these results did not find a prophylactic 
benefit for the use of the cream, it did suggest that its use could benefit the client by 
limiting the severity of the skin reaction allowing the clients to continue their treatment 
plan uninterrupted and thus receive the benefits of the full cumulative effect of the 
radiation therapy. 
Fisher and colleagues (2000) reported the results of a randomized study of 172 women 
receiving radiation therapy post-mastectomy/lumpectomy comparing the use of Biafine ® 
burn cream with the participating clinic's choice of best supportive care product or no-
treatment. Best supportive care product choices included Aquaphor ® (31%) and Aloe 
Vera (34%). Sixteen percent of the participants had no treatment to the treatment field 
(Fisher et al, 2000). While this study did not support the superiority of the use of Biafine 
® over the comparative products, it did suggest that the use of this cream hastened the 
healing of the skin reactions in women with large breasts and in the nonsmoking (Fisher 
et al, 2000). 
Aloe Vera 
A study was found that evaluated the effects of aloe vera gel as a prophylactic agent in 
ameliorating radiation dermatitis. One hundred ninety-four clients were double blind 
randomized into groups to receive a 98% pure aloe vera gel or an inert gel (used as the 
base of the aloe vera gel). Both the clients and healthcare providers rated the irradiated 
skin field on a weekly basis with a four-point scale being used. This study found no 
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statistical evidence to support the use of aloe vera gel; however, some of the healthcare 
providers questioned the historical decrease of radiation dermatitis during the twelve-
month study period. A second study was then used with one hundred eight clients 
randomly selected to either apply the aloe vera gel or not. The same rating scale for 
clients and healthcare providers was used with no clinically significant difference seen in 
the development or severity of radiation-induced skin changes (Williams et al. 1996). 
Acemannan 
Acemannan-containing wound gel dressings were applied to the irradiated skin fields 
of mice by Roberts and Travis (1995). They found that mice that were treated before the 
onset of skin erythema were much less likely to develop adverse skin reactions than those 
whose treatment was delayed until the onset of symptoms. They found the application of 
the gel was most effective when it was applied immediately after the irradiation of the 
skin. If application was delayed until manifestation of symptoms occurred, the gel did not 
prevent the progression of the dermatitis; however, those who continued to apply the gel 
healed at a faster rate than those groups who used no gel, personal lubricating jelly (K-
Y), or Aquaphor ® a prescription healing ointment. It was also noted that application of 
the gel to mice in the other groups after severe acute dermatitis had developed did not 
improve healing time. 
Summary 
The effects of radiation on the skin and breast tissue are known and described in the 
professional literature (Appendix A-2). Prognostic indicators for severe skin reactions to 
irradiation have been researched with encouraging results. While much has been written 
about the treatment of radiation-induced skin reactions, little has been done to discover an 
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agent that could prevent the development of these reactions despite the potentially 
detrimental effects of radiation-induced skin reactions on the client's skin, interruption of 
treatment and the severe long-term effects associated with the development of acute skin 
reactions including infection, necrosis and loss of healthy breast tissue. 
Chapter III 
Methods 
In this chapter, the methods and design for the study will be described. The design, 
instruments, setting and sampling, data collection, ethical considerations involved and 
data analysis will be explained. Limitation of the study's internal and external validity 
and attempts to control these factors will also be addressed. 
Design 
In this descriptive study, clients were instructed to apply Radiacare ® gel to the 
radiation treatment area at least two to three times daily from the initial consultation until 
four weeks after the completion of treatment. Skin reactions within the treatment area 
were assessed weekly and scored based upon the Oncology Nursing Society's skin 
reaction scale (Bruner et al, 1998). Skin reactions were analyzed and compared to the 
known high risk factors of large breast size, increased length of surgical incision and 
recent chemotherapeutic exposure as well as suggestive factors of age and weight 
changes. It is known that application of this gel is effective in the treatment of radiation 
treatment induced skin reactions; this study was to determine if application from the start 
of radiation treatment may prevent the occurrence of radiation-induced skin reactions 
(Plenums, et. al, 1994). 
Instruments 
A data assessment form (Appendix 1) was used to document the skin assessment for 
participants throughout their treatment plan. Information about the suggestive factors of 
breast size, exposure to chemotherapeutic agents, length of incision, age and weight was 
recorded as well as a weekly assessment of the treatment skin area including the entire 
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breast, axillary and inframammaiy skin folds, and the surgical incision areas. The skin 
reaction was scored according to the Oncology Nursing Society's skin assessment scale. 
The client's age, weight changes, and skin complexion type, bra size and previous 
exposure to chemotherapeutic agents were recorded for comparison purposes. 
Breast Size 
Since the inframammary skin fold has been identified as a high-risk area for radiation 
induced skin reactions in women with larger breasts, clients receiving post-lumpectomy 
irradiation will be asked to identify their post-operative brassiere cup size. Large breast 
size was identified as C-cup size or larger. 
Radiosensitizing Agents 
A list of the client's current medication regimen was obtained, and each drug will be 
assessed for its degree of radiosensitivity. In addition, a history was taken to determine if 
known radiosensitizing chemotherapeutic agents such as dactimomycin, doxorubicin, 
methotrexate, 5-flurouracil, and/or hydroxyurea were used (Bruner et. al, 1998). The 
time lapse since chemotherapeutic exposure was recorded. 
Incision Length 
The length and location of each participant's surgical scar was obtained and recorded 
in centimeters. The location was identified by the quadrants of upper lateral (including 
tail of Spence), upper medial, lower lateral, and lower medial as well as mixed superior, 
inferior, lateral or medial. Clients with edema, erythema, or an open, draining wound in 
the treatment area at the onset of therapy were excluded from the study. 
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Age 
Age has been identified in previous studies as a contributing factor in the decreased 
healing time for radiation dermatitis and other skin integrity problems. It was included in 
this study to explore the relationship between age and the development of radiation-
induced skin reactions when Radiacare® gel is applied according to the study's protocol. 
Weight Changes 
Studies have linked poor nutritional status to both loss of skin integrity and delayed 
wound healing. A comparison of baseline body weight and weekly weights was 
included. It is acknowledged that the assumption of good nutritional status before 
diagnosis is idealistic. 
Skin Complexion Type 
Although radiation-induced skin reactions affect the basal layer of skin, anecdotal 
data suggest that fairer complexions are more likely to experience the more severe skin 
reactions. This comparison was made by having the skin complexion type assigned by 
the client's self-report based upon the following scale: 
Fair: burns easily with minimal sun exposure 
Medium: burns with sun exposure but rarely blisters 
Dark: rarely burns with sun exposure 
Radiation Dose 
Each client's cumulative weekly radiation dosage was recorded. Differences in 
treatment length and area were compared. Breaks in consecutive treatments were also 
recorded with a rationale for its need. 
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Skin Assessment 
In 1994, the Oncology Nursing Society adopted a six-point skin assessment scale for 
radiation-induced skin reactions (Bruner et. al, 1998). The scale allows for 
standardization and improved communication between practitioners. Documentation of 
skin reactions were identified as 
0 = No changes noted 
1 = Faint or dull erythema, follicular reaction 
2 = Bright erythema 
3 = Dry desquamation with or without erythema 
4 = Small to moderate amount of wet desquamation 
5 = Confluent moist desquamation; edema 
6 = Ulceration, hemorrhage, or necrosis 
For this study, the entire treatment area, axillary skin fold, inframammary fold, and 
area adjacent to the surgical incision were assessed. Any skin reaction was graded and its 
location noted on the data collection form. 
Setting and Sampling 
The participants of this study were selected from an outpatient radiation oncology 
clinic in the southeastern United States. All clients who were referred for post-
lumpectomy or post-mastectomy irradiation were asked to participate. Those who had a 
known sensitivity to aloe vera, were unable or unwilling to comply with the application 
of the gel, had edema, erythema or an open wound to the treatment area were excluded 
from the study. 
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Intervention 
Each participant was given a skin care protocol (Appendix 3) that included the 
application of the Radiacare ® gel. Sample tubes of the gel were provided along with a 
prescription for additional tubes. Each week, the client was asked about application of 
the gel and the clinic nurse, using the above-mentioned Oncology Nursing Society scale, 
assessed the skin for reactions. 
Data Collection 
Upon signed consent to participate (Appendix 4), the client was asked to identify her 
age, weight change since diagnosis, skin complexion type, post-operative bra size and 
exposure to chemotherapeutic agents. The clinic nurse recorded medications, herbal 
supplements and vitamins in use, measured and identified the location of the surgical scar 
and assessed the treatment area skin. A data collection sheet (Appendix 1) was placed in 
the chart. Each week, the client was asked to confirm continued use of the gel. The nurse 
assessed the treatment area skin and recorded the assessment of the breast fields, weight, 
medication changes and cumulative radiation dose. After the four-week follow-up 
appointment, the form was removed from the chart and the data was transferred to a tally 
sheet from which comparison to that of other participant's data was made. At the 
conclusion of the study, each participant's data was tabulated and reported. A 
comparison of skin reactions each week and between each risk factor was examined 
Comparisons were made as to the influence the application of the gel may have had on 
the participant's skin. All results are given in grouped data to decrease the chance of 
individual identification of a participant. 
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Ethical Considerations 
This study included human participants and was reviewed by the university's Human 
Subjects Review Board (Appendix 5) as well as the Medical Center's Research Review 
Committee (Appendix 6). The treatment under study has been the standard treatment 
protocol within this population for the clinic since February 2000 and was conducted to 
evaluate its clinical validity (Appendix 7). 
Participants were solicited from the clients referred to the clinic for post-mastectomy 
or post-lumpectomy irradiation. Each client had the study explained to them by the 
researcher and was asked to provide a written consent to participate (Appendix 4). The 
participants were given a copy of the consent, which included the procedure for 
withdrawal from the study. Care was taken to stress that participating in the study would 
merely allow the data collected to be used for research purposes and would not change 
the skin care recommendations they received. After the participant's one-month follow-
up appointment was completed, her data assessment form was removed from the chart to 
ensure anonymity of the data. 
Data Analysis 
The data analysis for this descriptive study included frequencies and the measures of 
central tendency including mean, median and mode. Comparisons between each 
suggestive factor and the degree of skin reaction were analyzed using Analysis of 




In this study, internal validity may be questioned since the selection of participants 
was based upon those who were referred to the clinic for irradiation during the study 
timeframe, those who consented to participate and those who were willing or able to 
continue to participate throughout the study. The lack of a control group and 
randomization in selection limit the ability to identify with confidence the use of the 
Radiacare ® gel as the influencing factor in the incidence of the development of radiation 
dermatitis. 
Sample Size 
Study participants were solicited from those clients (all women) who were referred for 
irradiation post-mastectomy or post-1 umpectomy during the study timeframe. There was 
no reliable mechanism for predicting the number of referrals that would be made within 
that period. 
Attrition 
As in any study, a certain amount of attrition is expected. There are those participants 
who may wish to withdraw, those from the sampling pool who are not eligible to 
participate, and those who do not complete the treatment plan. This attrition factor will 
decrease the already limited sample size and will have a negative effect on the 
generalizability of any relationships identified. 
Subjectivity of Skin Reaction Analysis 
The use of the Oncology Nursing Society's skin assessment scale, while helpful, does 
not eliminate the subjectivity of the skin reaction scores. To minimize this effect, the 
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number of persons who assessed the scores was limited to the two researchers who are 
Registered Nurses, employed by the clinic and are familiar with the study and its purpose. 
Further validation was provided by the medical director's independent assessment of the 
skin condition. 
External Validity 
The external validity of this study is threatened since random selection of participants 
was not used. This approach prevents generalization to the population of all clients 
receiving external beam radiation therapy post-lumpectomy or mastectomy. Multiple 
treatment interference may also threaten the external validity in that it is not known what 
cumulative effects of prior treatments (such as chemotherapy) or other current treatments 
may have had on the development of radiation dermatitis. 
Setting and Sampling 
It was expected that the clients for this study would be primarily female, Caucasian 
and over the age of 60, thereby limiting its generalizability to the entire population; 
however, it does reflect the profile of those with breast cancer that are receiving post-
surgical irradiation. This study was conducted within a mid-sized regional medical 
center in the southeastern United States, which may influence the demographic reliability 
of generalization to more rural or urban settings, or to those with more ethnic diversity. 
Reactive Effect 
While it is vital that clients be aware of and consent to participation in this study, this 
requirement may not only limit the size of the sample but may also influence the 
subjective data required from the participants, especially the validity of the self-reporting 
of the continued use and frequency of use of the gel throughout the treatment. 
26 
Summary 
The design of this descriptive study was to maximize the available data and minimize 
factors that could distort the validity of the findings. A review of the literature was 
conducted to determine those factors identified as suggestive or directly implicated in the 
development of radiation-induced skin reactions and were included in this study to 
discover the relationship between the application of the Acemannan containing Radiacare 
® gel and the prevention of the development of these skin reactions. Care was taken to 
control those factors that could influence the data collection and analysis as well as limit 
the generalizability of the findings to the general population. It was the purpose of this 
study to determine if there is a relationship between the application of this gel and the 
prevention of the development of radiation dermatitis in participants with intervening 
factors such as large breast size, exposure to radiosensitive agents, healed surgical 
incisions, advanced age and weight changes since diagnosis. 
Chapter IV 
RESULTS 
Between April 1,2001 and October 31,2001, 19 eligible clients were solicited for 
participation in the study. One declined and the remaining 18 were followed throughout 
their treatment regimen. Demographically, 89% of the women (n=16) were of European 
ancestry and 11% (n=2) were of African decent. There was no attrition. Twelve women 
identified their breast cup size as cup-C or larger and the affected breast was equally 
distributed between the right and left side. Five participants were treated with 
chemotherapy before the onset of their radiation. No woman in this study received 
concurrent chemotherapy with the external beam radiation. The incision size ranged 
from 2.5 cm to 12.5 cm with a mean of 5.9 cm. All but one of the participants was 
receiving post-lumpectomy irradiation with two thirds of the incisions being located on 
the lateral aspect of the affected breast. The age range of the participants was 30 - 87 
with a mean age of 56.7. Five clients were aged 30 - 49; nine were between the ages of 
50 - 69, and the remaining four were aged 70 - 89. Most women (n=13) claimed no 
weight change from the time of initial diagnosis until the onset of radiation therapy. Of 
those who did report a change, three cited a weight loss (-2, -5,-10 pounds) while two 
indicated they had experienced a weight gain (+5, +10). At the conclusion of the 
treatment plan, the mean weight change was a loss of 5.3 pounds. Five questions were 
addressed with this study and statistical data collected and analyzed to discover the 





What is the relationship between large breast size and the incidence of radiation 
dermatitis when using Radiacare® gel before and throughout external beam radiation 
therapy? 
Analysis of Variance indicated that there was no relationship between the incidence of 
radiation dermatitis within the entire treatment field (p=0.741) between large-breasted 
women and small-busted; however, there was a stastically significant difference noted 
between those groups at both the area around the incision site and the inframammary skin 
fold. Women with size C-cup breasts or larger were likely to have a more intense skin 
reaction along the incision line (p=0.0249) or the inframammary fold (p=0.0180) than 
those who were smaller busted. Since this finding has been reflected in prior studies, the 






Mean Incidence by Cup Size 
• < C-cup 
• > C-Cup 
1 -: • i a • • r - m 
Breast Incision IMF Axilla Incidence 
< C-cup 5.3 5.2 4.3 5.2 20 
> C-Cup 7.4 7.6 9.7 7.6 32.3 
Figure / : Comparison of incidence of radiation dermatitis between large-breasted and 
small-breasted women throughout treatment field (incidence), and at the breast, 
incision, inframammary skin fold, and axillary sites. 
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Question Two 
What is the relationship between prior exposure to chemotherapeutic agents and the 
incidence of radiation dermatitis when using Radiacare® gel before and throughout 
external beam radiation therapy? 
No relationship was seen between the women who had prior exposure to 
chemotherapeutic agents and those who did not (figure 2). Incidence was determined by 
calculating the total of the skin severity reactions at each site (entire breast, incision line, 
inframammary fold and axilla, where applicable) throughout the treatment period then 
compared by groups (chemo and non-chemo) with no stastical difference found. 
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Figure 2. Comparison of total incidence of skin reaction by entire breast, area 
surrounding the incision, the inframammary skin fold and mean incidence between 
those who were exposed to chemotherapeutic agents prior to irradiation and those 
who were not. 
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Question Three 
What is the relationship between the length of incision and the incidence of radiation 
induced dermatitis when using Radiacare® gel before and throughout external beam 
radiation therapy? 
Using the Pearson's Correlation Coefficients, the length of the scar was able to 
account for less than 1% of the skin reaction of the total treatment field (R2=0.616) and 
for less than 2% of the reaction seen around the incision line (R2=0.02). Of interest, a 
negative correlation (r=-0.08141) was seen between the incision length and the incidence 
of skin reaction at the inframammary skin fold (Figure 3). This end result could indicate 
a positive relationship between the use of Radiacare ® gel and the decrease in the skin 
reaction at the inframammary skin fold. 
Incidence by Incision Size 
60 





Individual reactions by site 
Figure 4. Total incidence of skin reaction by site (axilla, inframammary skin fold, 
area surrounding the incision, and entire breast) for each participant. 
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Question Four 
What is the relationship between the age of the client and the incidence of radiation 
dermatitis when using Radiacare® gel before and throughout external beam radiation 
therapy? 
Figure 4. Incidence of skin reaction totals by age of client. 
The relationship between age of the client and the incidence of radiation dermatitis 
(figure 4) in this study was mixed. The data indicated a positive correlation between age 
and the skin reaction incidence over the entire treatment field (r=0.01841). The data also 
showed a negative correlation between incidence and the area around the incision line 
(r=-0.03169) and the inframammary fold (r= -0.039331) that is, as age increased, a lower 
incidence of radiation dermatitis occurred in each of these observation sites (figure 5). 
The study findings indicate the possibility that a favorable relationship exists between the 
use of Radiacare ® gel and the incidence of radiation dermatitis at the incision line and 
inframammary fold in older women. 
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Figure 5. Comparison of the incidence of skin reaction and age of the client by 
contrasting reaction at the inframammary skin fold and incisional area. 
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Question Five. 
What is the relationship between weight changes since diagnosis and the incidence of 
radiation dermatitis when Radiacare® gel before and throughout external beam 
radiation therapy? 
A positive relationship between the weight changes and the incidence of radiation 
dermatitis was seen with the use of Radiacare ® gel (figure 6). By Pearson's Correlation 
Coefficient, 14% of the skin reaction over the entire treatment field was correlated to 
weight changes (r= -0.37524), 8% of the reaction seen around the incision site 
(r= -0.28978) and 3.7% of the inframammary skin fold reaction (r= -0.19274). As weight 
decreased, the skin was less likely to react. The suggestion is that the Radiacare® gel 
may have positively affected the degree of skin reaction in this group of participants. 
Incidence by Weight Changes 
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weight change since diagnosis 
Figure 6. Comparison of total skin reaction to amount of weight change since breast 
cancer diagnosis by participant. 
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Summary 
The overall goal of this study was to determine if the use of Radiacare® gel before 
and throughout treatment with external beam irradiation following a mastectomy or 
lumpectomy for breast cancer would alter the expected skin reaction. A review of 
literature identified factors that could be used to identify persons or areas most at risk for 
intense skin reactions from the treatment. The use of Radiacare® gel did not change the 
skin reaction intensity from that which was expected in women with larger than C-cup 
breasts; however, results showed a positive relationship among women who had 
undergone chemotherapy before radiation therapy, who were older or who had lost 
weight since breast cancer diagnosis and decreased skin reaction. 
Chapter V 
Discussion 
In this descriptive study, the effects of the application of Radiacare® gel before and 
throughout external beam radiation therapy post-lumpectomy or post-mastectomy were 
evaluated to determine if there was a difference in skin reactions from those described in 
the literature. Many prognostic indices were suggested as factors that negatively 
influenced the development of radiation dermatitis during therapy. Five risk factors were 
selected from these to be used in this study and were identified as follows: breast size of 
C-cup or larger, previous exposure to chemotherapeutic agents, length of surgical 
incision, age, and weight change since diagnosis with breast cancer. The small sample 
size and lack of a control group limit the generalizability of the findings; however, these 
risk factors should be used to guide future studies since the use of the Radiacare® gel 
may have positively influenced the degree to which the skin reacted during treatment. 
Breast size 
When assessing the skin reaction of women with C-cup or larger breasts receiving 
external beam radiation therapy post-lumpectomy, there were more intense skin reactions 
noted at the incision line and the inframammary skin fold than those seen with smaller 
breasted women in the group. However, there was no stastically significant difference in 
the overall treatment field when compared with the smaller breasted women receiving 
treatment. It was expected that the larger breasted women would have significantly more 
intense reactions in every assessed area (when compared with the smaller breasted 
women under treatment); therefore, the possibility that Radiacare® gel positively affected 
the skin in the larger breasted group can be considered. Of note, during this study, only 
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one woman (size EEE) required a break in the treatment plan due to radiation dermatitis. 
This factor is one that should be included in future studies of this nature, as the 
cumulative benefit of irradiation has long been documented as most effective in treating 
tumors and interruption in treatment may decrease the effectiveness of the irradiation. 
Prior chemotherapeutic agent exposure 
The prior exposure to chemotherapeutic agents was expected to increase the incidence 
of skin reaction; however, in this study, there was no statistically significant difference 
found when assessing the treatment field, axillary, inframammary fold, or incision areas. 
While the study's design and sample size cited previously prevent generalizability, it is 
possible to speculate that the use of the Radiacare® gel may have had a positive influence 
on this factor. Future studies using control groups and random assignment to treatment 
modalities should identify the role Radiacare® gel application plays in the decreased 
incidence of radiation dermatitis. 
Length of surgical incision 
It was expected that those with larger surgical incisions would have greater skin 
reactions due to the breech of skin integrity before the insult of irradiation. Each 
participant was required to have a well-healed incision without a break in the skin to be 
eligible for participation in this study. The length of surgical incision was able to account 
for less than two percent of the skin's reaction in this study. It is possible that a larger, 
more randomly selected population would reflect a different correlation. In this study, a 
negative correlation was seen between the larger surgical incisions and skin reaction 
incidence at the inframammary fold. This finding could be a serendipitous one, or, could 
suggest that the Radiacare® gel applied to this area afforded some skin protection. 
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Age of client 
As with the increased incidence of skin reaction expected with a breech in the 
integrity of the skin, it was expected that older skin would have more intense skin 
reactions due to the loss of elasticity, moisture and slower recovery time from insults. 
When assessing the overall treatment fields, the incidence of skin reaction did rise with 
the age of the client; however, the areas of the inframammary skin fold and surgical 
incision had a negative correlation suggesting that the application of the Radiacare® gel 
may have had beneficial effect on these treatment areas. A larger, more comprehensive 
study should investigate this phenomenon. 
Weight change since diagnosis 
The final prognostic factor evaluated in this study was the relationship between weight 
change and the incidence of skin reactions when using Radiacare® gel before and 
throughout treatment. Prior studies have indicated that poorly nourished skin is less 
pliable and slower to heal than well-nourished skin and that the nutritional status of the 
client before the onset of treatments will influence how well the skin is able to protect 
and repair itself from the damage caused by the radiation. This study utilized a self-
report of the amount of weight change since diagnosis combined with the actual 
beginning and ending weights to define weight changes. Future studies may consider the 
use of other determinations of nutritional status or Body Mass Index (BMI) to estimate 
this factor. In this sample few clients reported a weight change, and the mean weight 
change throughout the twenty-five consecutive treatments was a loss of five pounds. The 
assumption that the women were nutritionally healthy at the time of diagnosis was 
unrealistically ideal. Even within the small sample size of this study, there were women 
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who were grossly underweight as well as those who were morbidly obese. This ideal 
weight assumption negates any correlations identified in this group. 
While the scope and limitations of this study, as previously identified, limit its 
usefulness, the results are encouraging in the potential of Radiacare® gel in preventing or 
minimizing the incidence of radiation dermatitis in women receiving external beam 
radiation therapy post-lumpectomy or post-mastectomy. This study's data analysis did 
indicate that of the factors under consideration, forty percent of a women's degree of skin 
reaction could be accurately predicted based upon knowing her breast cup size and the 
amount of weight change she had experienced since her diagnosis. Incidentally, the data 
also supported previous findings stating that fair skin complexion is not an accurate 
prognostic factor for intensity of skin reactions while receiving external beam irradiation. 
Suggestions for future studies 
Suggestions for future studies include the use of a larger sample size with a control 
group and more ethnic diversification of the population. In addition, the use of BMI or 
other measure of nutritional status rather than weight change since diagnosis is 
recommended. An objective means of recording a comparison of the number of and 
amount of applications applied daily would assist researchers in evaluation of data. 
Additionally, studies should analyze the frequency and duration of treatment breaks 
caused by acute skin reactions, as well as time of healing of the skin back to baseline. 
The participants in this study were primarily middle-aged Caucasian women of 
middle- to upper-middle class socioeconomic status. A larger, more diverse population 
may illicit significantly different results or may confirm those suggested in this study. As 
noted previously, a more accurate measure of nutritional status is needed to better 
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evaluate the degree to which the skin's nutritional health influences the incidence of skin 
reactions during irradiation therapy. 
The daily use of the gel and number of applications per day were self-reported and 
were, therefore, subject to reactive effect. A study to compare the amount of gel applied 
and/or the number of applications per day would be useful in guiding skin care protocols 
using this product if further research indicates its usefulness in the prevention of or 
decreased incidence of skin reactions. 
Future studies should include an indication of the number of participants who are 
required to have a break in the treatment regime due to severe skin reactions when 
compared to a control group. If the use of this gel can prevent a break in treatment, then, 
women who use this product would be able to gain the full benefit of the cumulative 
effects of their therapy. 
Summary 
This descriptive study identified and evaluated five prognostic indicators of radiation 
dermatitis in women receiving external beam radiation therapy post-lumpectomy or post-
mastectomy. While the small sample size and lack of a control group limits the 
usefulness of the findings, there were indications that the use of Radiacare® gel may 
have positive outcomes in preventing the occurrence radiation dermatitis or alleviating 
the symptoms which promote treatment adherence and improved quality of life for the 
client receiving treatment. 
The nurse working within the radiation/oncology clinic may also use this study's 
findings to reinforce skin care protocols with those women with large breasts. 
Additionally, the oncology nurse should identify those with weight changes since breast 
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cancer diagnosis because this factor has been identified as putting the individual at 
significant risk of more severe skin reactions. Those women with both risk factors would 
be especially encouraged to adhere to the skin care protocols. 
Future studies should include these factors when comparing the use of this gel to 
another or a control group with no treatment to assist in evaluating its effectiveness. 
They should also include a more ethnically diverse population and a better mechanism 
for identifying nutritional status. It is also recommended that the number of breaks in 
treatment required due to severe skin reaction be compared. 
Nurses assist women in dealing with the devastating emotional, spiritual, and physical 
effects that encompass the diagnosis and treatment of breast cancer. It is imperative for a 
product to be found that will prevent or alleviate the uncomfortable and sometimes 
debilitating skin side effects experienced by women receiving external beam radiation 
therapy for their cancer. Knowledge of the prognostic factors for more severe skin 
reactions will be useful to the oncology nurse only if a product can be identified to offer 
prevention or palliation of those symptoms. Nurses must encourage participation in 
future studies to assist in the continued search for help for the suffering of the clients 
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Radiacare Project Form 
Thank-you for agreeing to participate in this study. Please identify the following information. 
Remember that once your treatment is completed, this form will be removed from your chart and 
no one will be able to tell it was yours. 
Personal Information: 
Gain 
Age: Bra Size: Amount of weight change since diagnosis: Loss 
Have you taken, or are you now taking, chemotherapy? Yes No 
If so, how long since treatment completed? 
Would you rate your skin complexion as? 
Fair: burns easily with minimal sun exposure 
Medium: burns with sun exposure but rarely blisters 
Dark: rarely burns with sun exposure 
For Nurse to complete: 
List of current prescription and over the counter medications: 
Scale: 0 = no changes noted 4 = small to moderate wet desquamation 
1 = faint or dull erythema, follicular reaction 5 = confluent moist desquamation; edema 
2 = bright erythema 6 = ulceration, hemorrhage, or necrosis 
3 = dry desquamation with or w/o erythema 
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Appendix A-2 
Literature Relevant to the use of Topical Agents to Treat Radiation Dermatitis 
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Rjilutum Oncology Gnitr 
Skin Care Instructions for Breast Cancer Radiation Therapy 
Radiation therapy works by exposing the cancerous area to high-energy x-rays. While both the diseased and 
healthy cells are affected, the healthy cells possess a better ability to recover and the diseased cells are damaged or 
destroyed. 
There are many things you can do to help make your treatment a success! 
1. Protect the treatment area from rubbing, pressure, or irritation. 
• Wear loose, soft cotton, comfortable clothes. (Old ernes that can get ink cm them!) 
• Do not wear a bra or tight clothing that will rub the treatment area. 
• Do not starch your clothes. 
• Do not rub or scrub the treatment area. Use your hands to gently cleanse the area. 
• Do not use adhesive tape on the treatment area. If you must bandage the area, use paper tape and 
try to apply it to an untreated part of the skin. 
• Try to keep your underarm from rubbing skin to skin—stand with your hand on your hip to keep 
the skin from your arm from rubbing your underarm. 
2. Protect the treatment area from irritants such as: 
• Soaps, perfumes, heating pads, ice packs, or talcum powder. 
• Use only the deodorant provided by the Radiation Oncology Nurse. 
• Avoid shaving the underarm of the treated side. If you MUST shave, use an electric shaver and DO 
NOT apply preshave lotions or hair remover products to the treatment side. 
3. Protect the treatment area from the sun during treatment and after the treatment is completed. During 
your treatment time, keep the area covered from sun exposure with light colored clothing. After 
treatment, we recommend using a PABA sunscreen with at least a 15 rating as well as covering the 
treated area with light colored clothing. 
4. Do not wash off the marks applied by the Radiation Therapists to outline the treatment area. 
5. Apply a thin layer of Radiacare gel to the inside of the outlined area FOUR TIMES A DAY beginning 
on the day the outline marks are made. Continue to apply the gel throughout the treatment until your 
one-month follow-up visit. The gel will protect the healthy cells from damage during treatment. It will 
supply the healthy cells with moisture and help them heal after treatment is complete. 
• On treatment days, do not apply the gel within TWO hours of treatment and apply the gel as soon 
as possible after your treatment to get the most benefit. 
• If itching or drainage develops, see die physician or nurse for the gel in a cooling or absorbent 
formula. 
6. Eat a healthy, balanced diet and drink plenty of fluids. 
7. Avoid people with colds or other infections until your treatment is over. 
8. Ask questions! Write them down and bring them with you to your treatment sessions and follow-up 
visits. You will see the Radiation Oncologist each week, usually on Wednesday, but please let us know 
if you have questions or concerns before then. 
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Appendix A-4 
INFORMED CONSENT DOCUMENT 
Project Title: Prevention of Radiation-Induced Dermatitis in Breast Cancer Irradiation. 
Investigator: Cathy Eden Ammerman, Nursing, 615.451.2817 
You are being asked to participate in a project conducted through Western 
Kentucky University and Sumner Radiation Oncology. The University requires that you 
give your signed agreement to participate in this project. 
Mrs. Ammerman or Mrs. Rippy will explain to you in detail the purpose of the 
project, the procedures to be used, and the potential benefits and possible risks of 
participation. You may ask her any questions you have to help you understand the 
project. A basic explanation of the project is written below. Please read this explanation 
and discuss with Mrs. Ammerman or Mrs. Rippy any questions you may have. 
If you then decide to participate in the project, please sign on the last page of this 
form in the presence of the person who explained the project to you. You will be given a 
copy of this form to keep. 
1. Nature and Purpose of the Project: 
The purpose of this study is to determine if the gel marketed under the name of 
Radiacare is effective in preventing the skin reactions that are sometimes seen in 
women who are having radiation therapy after their mastectomy or lumpectomy. 
2. Explanation of Procedures: 
You will be given a copy of the clinic's skin care guidelines including applying 
the Radiacare Gel to the treatment site two or three times a day beginning today 
and continuing to apply the gel to that area for one month after your treatments 
have ended. Each week (usually on Wednesdays) you will be asked how many 
times a day you are applying the gel and your skin will be checked for signs of 
redness and swelling. 
3. Discomfort and Risks: 
If using aloe vera in the past has caused you to develop hives or caused redness or 
swelling to your skin or you have had a previous adverse reaction to Radiacare 
Gel, you should not use this product. There is a slight chance that you may 
develop redness, swelling, or hives to the treatment area if you develop an allergy 
to the gel. If you do, you will be advised to stop using the gel and your 
information will not be used in the study except to say one person was not able to 
complete the study due to an adverse skin reaction to the gel. 
4. Benefits: 
It is anticipated that the application of this gel will prevent skin damage from your 




A form like the one attached to this one will be placed in your chart upon which 
the nurse will track your skin response each week. This form will also have your 
age, bra cup-size, size of surgical scar, and list of your current mediations. This 
information has been included to determine whether these factors change the 
effectiveness of the gel in preventing skin reactions. No one except the persons 
employed by the radiation clinic will be able to view the form. Once you have 
completed your one-month post-treatment appointment, that form will be 
removed from your chart, the skin reaction scores and above-mentioned 
information will be placed on an anonymous form and the one in your chart will 
be destroyed. No one will be able to determine your individual results once your 
follow-up appointment is completed. 
6. Refusal/Withdrawal: 
Refusal to participate or withdrawal from the study does not alter the skin care 
guidelines for you. If you do not wish to continue your participation in the study, 
you may withdraw from the study at anytime during your treatments until the time 
of your one-month follow-up appointment. Once your information has been 
transferred to the anonymous group form, it cannot be removed. 
Withdrawal may be done in person by informing the nurse of your decision to 
withdraw any day during your treatment or upon your one-month follow-up visit. 
Refusal to participate in this study will have no effect on any future services you 
may be entitled to from the University or the Radiation Oncology Clinic. Anyone 
who agrees to participate in this study is free to withdraw from the study at any 
time with no penalty. 
I understand also that it is not possible to identify all potential risks in an experimental 
procedure, and I believe that reasonable safeguards have been taken to minimize both the 
known and potential but unknown risks. I also understand that my participation in this 
study is voluntary. 
Signature of Participant Date 
Witness Date 
THE DATED APPROVAL ON THIS CONSENT FORM INDICATES THAT 
THIS PROJECT HAS BEEN REVIEWED AND APPROVED BY 
THE WESTERN KENTUCKY UNIVERSITY HUMAN SUBJECTS REVIEW 
BOARD 
TELEPHONE: (270)745-4652 
YOU MAY CONTACT THE HUMAN PROTECTIONS ADMINISTRATOR AT 
THIS NUMBER 
SHOULD YOU HAVE COMMENTS OR CONCERNS 
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Appendix A-5 
APPLICATION FOR APPROVAL OF INVESTIGATIONS 
INVOLVING THE USE OF HUMAN SUBJECTS 
Submit by the first working Monday of the month for screening prior to the HSRB 
meeting. Please add additional space between items as needed to describe your 
project. 
1. Principal Investigator's Name: Cathy Eden Ammerman, RN 
Email Address: cathyea@home. com 
Mailing Address: 811 Harden Street Gallatin, Tennessee 37066 
Department: Nursing Phone: (615)451-2817 
Co-Investigator: Carol B. Rippy, RN, C 
Email Address: rippyc@sumner.org 
Mailing Address: 300 Steam Plant Road, Suite 150 Gallatin, Tennessee 37066 
Department: Sumner Radiation/Oncology Phone: (615) 451 -6080 
2. If you are a student, provide the following information: 
Faculty Sponsor: Dr. Beverelv E. Holland. Nursing Phone: (270) 745 - 3489 
Faculty Mailing Address: AC 108-A 1 Big Red Way Bowling Green, KY 42101 
Student Permanent Address (where you can be reached 12 months from now): 
811 Harden Street Gallatin, Tennessee 37066 
Is this your thesis or dissertation research? Yes 
3. Title of project: Prevention of Radiation-Induced Dermatitis in Breast Cancer 
Irradiation. 
4. Project Period: Start: May 1.2001 End: October 31,2001 
5. Has this project previously been considered by the HSRB? NO 
6. Do you or any other person responsible for the design, conduct, or reporting of 
this research have an economic interest in, or act as an officer or a director of, any 
outside entity whose financial interests would reasonably appear to be affected by 
the research? NO 
7. Is a proposal for external support being submitted? NO 
8. You must include copies of all pertinent information such as, a copy of the 
questionnaire you will be using or other survey instruments, informed consent 
documents, letters of approval from cooperating institutions (e.g., schools, 
hospitals or other medical facilities and/or clinics, human services agencies, 
individuals such as physicians or other specialists in different fields, etc.), copy of 
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external support proposals, etc. Attached: Informed consent document, Letters of 
approval from Sumner Regional Medical Center, and Dr. Robert T. McClure, 
Radiation/Oncology. 
I. PROPOSED RESEARCH PROJECT 
A. Provide a brief summary of the proposed research. Include major hypotheses and 
research design. 
Descriptive study of the effects of applying Acemannan (Radiacare Gel) in the 
prevention of the development of radiation-induced skin reactions in women 
receiving post-lumpectomy/mastectomy external beam radiation therapy at an 
outpatient radiation oncology clinic. 
Women will be asked to participate in the study and will be given a skin care 
protocol that includes the application of Acemannan to the skin within the 
treatment area. The skin will be assessed and assigned a reaction score weekly 
throughout treatment and at the one month follow-up appointment. 
B. Describe the source(s) of subjects and the selection criteria. Specifically, how 
will you obtain potential subjects, and how will you contact them? 
All clients receiving post-lumpectomy/mastectomy irradiation at Sumner 
Radiation/Oncology between May 1,2001 and October 31,2001 will be asked to 
participate. The clients will be solicited for participation at the time of initial 
consultation and simulation at which time the nurse will review the skin care 
protocol and explain the study. 
C. Informed consent: Describe the consent process and attach all consent documents. 
A written consent which explains the study and skin care protocol will be given to 
each prospective client. Emphasis will be placed upon the fact that participation 
does not alter the plan of care. See Appendix. 
D. Procedures: Provide a step-by-step description of each procedure, including the 
frequency, duration, and location of each procedure. 
1. Clients will be identified from new client referral list by nurse and request for 
participation consent will be placed in chart with usual educational materials. 
Once the clients have been deemed appropriate candidates for the ERBT, their 
participation in the study will be solicited. 
2. Clients who consent to EBRT will then be advised of skin care protocol 
including the application of Acemannan {Radiacare Gel) and will be solicited 
to participate in the data collection study. Care will be taken to emphasize 
that the treatment plan will not be altered by their participation or their 
decision not to participate. 
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3. Clients will be given sample tubes of the gel and a prescription for the gel 
by the medical director with instructions to apply a thin layer to the 
treatment area two to three times daily beginning with the initial 
consultation and continuing until the four-week follow-up visit. 
D. Procedures (cont.) 
4. Skin within the treatment area will be assessed on a weekly basis and 
again at the four week post-treatment follow up appointment and assigned 
a score based upon a six-point scale from 0 (no reaction) to 6 (necrosis). 
5. In addition data regarding, age, weight, bra cup size, size of surgical scar, 
skin complexion, and a list of current medication (including 
chemotherapy) will be collected to compare skin reaction severity within 
sub-groups. Each of these factors has been implicated in influencing skin 
reactions to EBRT. 
E. How will confidentiality of the data be maintained? (Note: Data must be securely 
kept for a minimum of three years on campus.) 
Information will be collected on a form that will include the client's initials 
during treatment and follow-up and kept in the client's treatment record. Once 
the follow-up visit is completed, the form's data will be transferred to a central 
tabulation form and the individual's form will be destroyed. Only healthcare 
personnel with legal 
access to the chart and the investigator will have access to the form during 
treatment. 
F. Describe all known and anticipated risks to the subject including side effects, 
risks of placebo, risks of normal treatment delay, etc. 
Acemannan has no known side effects. It has been FDA approved in the healing 
of radiation induced skin reactions. Since there is no approved prophylactic 
treatment for radiation induced skin reactions, the standard treatment is to treat 
the skin symptomatically. 
G. Describe the anticipated benefits to subjects, and the importance of the knowledge 
that may reasonably be expected to result. 
Acemannan has been shown to significantly reduce the radiation skin reactions in 
laboratory mice. It is anticipated that similar benefits will be obtained in human 
subjects. Acemannan is thought to support the monocytes and phyagocytic 
action to improve the skin's ability to repair itself from the damages of 
irradiation. The hydrogel properties of the gel are also thought to support 
retention of moisture within the skin (Roberts and Travis, 1995). 
n SIGNATURES 
I certify that to the best of my knowledge the information presented herein is an 
accurate reflection of the proposed research project. 
Principe Investigator Date 
Co-Investigator " U Date 
Approval by faculty sponsor (required for all students): 
I affirm the accuracy of this application, I accept the responsibility for the conduct of 
this research, the supervision of human subjects, and maintenance of informed consent 
documentation as required by the HSRB. 
Date 
Approval by Department Head (required for all applications) 
I confirm the accuracy of the information stated in this application. I am familiar with, 
and approve of the procedures that involve human subjects. 
— i - - Ql 
Department Head Date 
Advising Physician*: 
I certify that I am a duly licensed physician in the State of Tennessee and that, acting 
as advising physician; I accept the pKfcgdures prescribed herein. , 
rMlfrm. t>A*/, 
Physician's Name and Signature Date / 
*Physician signature is needed only if the project involves medical procedures and the 
investigator is not a licensed physician. 
03/30/01 
Western Kentucky Univeristy 
Bowling Green, KY 
To Whom It May Concern: 
The purpose of this letter is to let you know that Cathy Eden Ammerman has Sumner 
Regional Medical Center's permission to conduct her study as outlined in her "Prevention 
of Radiation-Induced Skin Reactions In Breast Cancer External Irradiation" proposal 
dated December 11, 2000. 
Nicole Brashear 
Vice President of Ancillary Services 
Post Office Box 1558 555 Hartsville Pike Gallatin, Tennessee 37066-1558 (615) 452-4210 
Sincerely, 
SUMNER RADIATION ONCOLOGY CENTER 
SUMNER REGIONAL HEALTH SYSTEMS 
300 STEAM PLANT RD. 
GALLATIN, TN. 37066 
March 30, 2 0 01 
RE: RESEARCH PROJECT 
To Whom I May Concern: 
This letter is in support of the Cathy Amraerman proposed research project on 
prevention of radiation induced dermatitis in breast cancer radiation. I am a 
radiation oncologist at Sumner Regional Medical Center. I have had the 
opportunity to work with Cathy when she filled in as our nurse during the 
maternity leave for our usual nurse. I think this would be an excellent 
research project and we would be glad to support Cathy in this endeavor. 
If I can be of any further assistance, please feel free to call. 
Sincerely yours, 
Robert McClure, M.D. 
Radiation Oncologist, Sumner Regional Medical Center 
/wsj 
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WESTERN KENTUCKY UNIVERSITY 
Human Subjects Review Board 
Office of Sponsored Programs 
104 Foundation Building 
270-745-4652; Fax 270-745-4211 
E-mail: Phillip.Mvers@Wku.Edu 
In future correspondence please refer to HS0195R, April 16, 2001 
Cathy Eden Ammerman, RN 
811 Harden Street 
Gallatin, TN 37066 
Dear Cathy: 
Your research project, "Prevention of Radiation-Induced Dermatitis in Breast Cancer Irradiation," was reviewed by 
the HSRB and it has been determined that risks to subjects are: (1) minimized and reasonable; and that (2) research 
procedures are consistent with a sound research design and do not expose the subjects to unnecessary risk. 
Reviewers determined that: (1) benefits to subjects are considered along with the importance of the topic and that 
outcomes are reasonable; (2) selection of subjects is equitable; and (3) the purposes of the research and the research 
setting is amenable to subjects' welfare and producing desired outcomes; that indications of coercion or prejudice are 
absent, and that participation is clearly voluntary. 
1. In addition, the IRB found that: (1) written informed consent will be required of subjects. (2) Provision is made 
for collecting, using and storing data in a manner that protects the safety and privacy of the subjects and the 
confidentiality of the data. (3) Appropriate safeguards are included to protect the rights and welfare of the 
subjects. 
Your research therefore meets the criteria of Expedited Review and is approved. 
2. Please note that the institution is not responsible for any actions regarding this protocol before approval. If you 
expand the project at a later date to use other instruments please re-apply. Copies of your request for human 
subjects review, your application, and this approval, are maintained in the Office of Sponsored Programs at the 
above address. Please report any changes to this approved protocol to this office. A Continuing Review 
protocol will be sent to you in the future to determine the status of the project. 
Director, OSP and 
Human Protections Administrator 
c: Human Subjects File0195R 
Dr. Beverly E. Holland, Department of Nursin: 
HSApprovalAmmermanHS0195R 
RECEIVED 
FEB 2 2 2002 
FOR HSRB USE ONLY: ~ O S P 
Application Number: HS0195 
Date of Original IRB Approval:04/16/01 
Level of Approval (please check one): • Exempt Expedited Q Full Board 
Was the project approved above or below minimum risk?: Below Q Above 
(If "Above" HSRB Chair and one other HSRB reviewer may determine whether the PI needs to appear before the HSRB). 
Name of Project:Prevention of Radiation-Induced Dermatitis in Breast Cancer Irradiation 
Name of Researcher:Cathy Eden Ammerman 
Department:Nursing 
Is your data collection with human subjects complete? 0 Yes Q No 
(If "Yes", please sign below and return to the Office of Sponsored Programs, Room 106, Foundation Building. If 
"No", please respond to the questions below, sign and return). 
Thank you. 
Continuing Review Checklist 
1. Has there been any change in the level of risks to human subjects? 
(If "Yes", please explain changes on a separate sheet). Q Yes Q No 
2. Have informed consent procedures changed so as to put subjects 
above minimal risk? (If "Yes", please describe on a separate sheet). Q Yes Q No 
3. How many subjects have participated in the project in the past year? # 
Have any subjects withdrawn from the research due to adverse 
events or any unanticipated problems? (If "Yes", please describe 
on a separate sheet). Q Yes Q] No 
4. Have there been any changes to the source(s) of subjects and the 
Selection criteria? (If "Yes", please describe on a separate sheet). Q] Yes Q No 
5. Have there been any changes to your research design that were not 
specified in your application, including the frequency, duration and 
location of each procedure. (If "Yes", please describe on a 
separate sheet). Q Yes Q No 
6. Has there been any change to the way in which confidentiality of the 
Data is maintained? (If "Yes", please describe on a separate sheet). Q Yes Q No 
.. r ^ c z ^ ^ 
Signature of Principal Investigator1 O U ^ l b CKQ-xx-
 D a t e 
^ v a l s ^ 
Signature of Reviewer " Date 
HSContinuingReviewFormRevisedO 1/22/02 
SK/02/18/02 
Date 
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